{"groups":[{"description":"Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"FG000","title":"Group 1 (CYT107, Atezolizumab)"},{"description":"Patients receive atezolizumab on Day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV","id":"FG001","title":"Group 2 (Atezolizumab)"},{"description":"Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"FG002","title":"Safety Run in Phase"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"comment":"Completed Study Treatment (up to 2 years)","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Safety Run-In Phase: If the treatment combination demonstrates an acceptable safety profile (one or fewer patient experiences a protocol-defined Dose Limiting-Toxicity), randomized enrollment will begin."}